eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2018
vol. 22
 
Share:
Share:
more
 
 
abstract:
Review paper

The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas

Cara Reiter-Brennan, Lukas Semmler, Andreas Klein

Contemp Oncol (Pozn) 2018; 22 (4): 215-222
Online publish date: 2018/12/31
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Mutation of the isocitrate-dehydrogenase (IDH) enzymes is one of the central research topics regarding gliomagenesis. Indeed, 70% of gliomas are associated with a gain-of-function IDH mutation and consequently synthesize the oncometabolite, 2-hydroxyglutarate (2-HG). This review aims to elucidate the effects of 2-HG on gliomagenesis. 2-HG promotes tumorigenesis by impacting metabolism, vascularization and altering the epigenome of glioma cells. Glioma metabolism and vascularization is altered by 2-HG’s effect on the stability of hypoxia-inducible factor (HIF) and inhibition of endostatin. However, 2-HG’s impacts on epigenetic mechanisms are more profound to gliomagenesis. Through competitive inhibition of JHDMs and TET proteins, 2-HG orchestrates histone and DNA hypermethylation, which is associated with gene silencing and dedifferentiation of cells. The hypermethylator phenotype induced by 2-HG also results in alterations of the interaction of the immune system with the tumour. Additionally, this study reviews 2-HG promotion of tumorigenesis by inhibiting repair of DNA alkylation damage through competitive inhibition of AlkB proteins.
keywords:

glioblastoma, cancer metabolism, epigenome, IDH1 mutation, 2-hydroxyglutarate

references:
Sanai N, Alvarez-Buylla A, Berger MS. Neural Stem Cells and the Origin of Gliomas. N Engl J Med 2005; 353: 811-822.
Hofer S, Bullinger L, Dierlamm J, et al. Gliome im Erwachsenenalter – Onkopedia, Berlin 2018. www.onkopedia.com/de/onkopedia/guidelines/gliome-im-erwachsenenalter/@@view/html/index.html (access: 07.12.2018).
Martinez R, Rohde V, Schackert G. Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol 2010; 96: 321-329.
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. JAMA 2013; 310: 1842-1850.
Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med 2009; 360: 765-773.
Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-744.
Yang H, Ye D, Guan K-L, Xiong Y. IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives. Clin Cancer Res 2012; 18: 5562-5571.
Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009; 118: 469-474.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131: 803-820.
Gao L. Glioma an overview of current classifications characteristics molecular biology and target therapies. Front Biosci 2015; 20: 4362.
Claus EB, Walsh KM, Wiencke, JK et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus 2015; 38: E6.
Scherer HJ. A critical review the pathology of cerebral gliomas. J Neurol Neurosurg Psychiatry 1940; 3: 147-177.
Ohgaki H, Kleihues P. The Definition of Primary and Secondary Glioblastoma. Clin Cancer Res 2013; 19: 764-772.
Leeper HE, Caron AA, Decker PA, et al. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget 2015; 6: 30295-30305.
Ward PS, Patel J, Wise DR, et al. The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting -Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
Cairns RA, Mak TW. Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities. Cancer Discov 2013; 3: 730-741.
Xu W, Yang H, Liu Y, et al. Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of -Ketoglutarate-Dependent Dioxygenases. Cancer Cell 2011; 19: 17-30.
Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012; 483: 484-488.
Chowdhury R, Yeoh KK, Tian Y-M, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011; 12: 463-469.
Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell 2010; 18: 553-567.
Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 2008; 4: 152-156.
Hausinger RP. Fe(II)/α-Ketoglutarate-Dependent Hydroxylases and Related Enzymes. Crit Rev Biochem Mol Biol 2004; 39: 21-68.
Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 1998; 8: 588-594.
Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1. Science 2009; 324: 261-265.
Fu Y, Zheng Y, Li K, et al. Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9. Biotechnol Lett 2012; 34: 441-446.
Yalaza C, Ak H, Cagli MS, et al. R132H mutation in IDH1 gene is associated with increased tumor HIF1-alpha and serum VEGF levels in primary glioblastoma multiforme. Ann Clin Lab Sci 2017; 47: 362-364.
Intlekofer AM, Dematteo RG, Venneti S, et al. Hypoxia Induces Production of L-2-Hydroxyglutarate. Cell Metab 2015; 22: 304-311.
Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
Böttcher M, Renner K, Berger R, et al. D-2-hydroxyglutarate interferes with HIF-1 stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization. Oncoimmunology 2018; 7: e1445454.
Williams SC, Karajannis MA, Chiriboga L, et al. R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1 upregulation in adult glioma. Acta Neuropathol 2011; 121: 279-281.
Kickingereder P, Sahm F, Radbruch A, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep 2015; 5: 16238.
Lando D. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002; 16: 1466-1471.
Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15: 2675-2686.
O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell 1997; 88: 277-285.
Fischer I, Gagner J-P, Law M, et al. Angiogenesis in Gliomas: Biology and Molecular Pathophysiology. Brain Pathol 2006; 15: 297-310.
Liu Y, Jiang W, Liu J, et al. IDH1 mutations inhibit multiple -ketoglutarate-dependent dioxygenase activities in astroglioma. J Neurooncol 2012; 109: 253-260.
Jones PA. Overview of Cancer Epigenetics. Semin Hematol 2005; 42: S3-S8.
Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
Wang Y, Leung FCC. An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics 2004; 20: 1170-1177.
Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006; 439: 811-816.
Füllgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene 2011; 30: 3391-3403.
Turcan S, Rohle D, Goenka A et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479-483.
Dong X, Weng Z. The correlation between histone modifications and gene expression. Epigenomics 2013; 5: 113-116.
Krishnan S, Horowitz S, Trievel RC. Structure and Function of Histone H3 Lysine 9 Methyltransferases and Demethylases. Chem BioChem 2011; 12: 254-263.
Venneti S, Felicella MM, Coyne T, et al. Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas. J Neuropathol Exp Neurol 2013; 72: 298-306.
Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474-478.
Song Y, Wu F, Wu J. Targeting histone methylation for cancer therapy : enzymes, inhibitors, biological activity and perspectives. J Hematol Oncol 2016; 9: 1-21.
Suva M-L, Riggi N, Janiszewska M, et al. EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance. Cancer Res 2009; 69: 9211-9218.
Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005; 6: 597-610.
Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1. Science 2009; 324: 930-935.
An J, Rao A, Ko M. TET family dioxygenases and DNA demethylation in stem cells and cancers. Exp Mol Med 2017; 49: e323.
Ye C, Li L. 5-hydroxymethylcytosine: a new insight into epigenetics in cancer. Cancer Biol Ther 2014; 15: 10-15.
Pfeifer GP, Xiong W, Hahn MA, Jin S-G. The role of 5-hydroxymethylcytosine in human cancer. Cell Tissue Res 2014; 356: 631-41.
Vasanthakumar A, Godley LA. 5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy. Cancer Genet 2015; 208: 167-177.
Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in Myeloid Cancers. N Engl J Med 2009; 360: 2289-2301.
Yang H, Liu Y, Bai F, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013; 32: 663-669.
Mercher T, Quivoron C, Couronné L, Bastard C, Vainchenker W, Bernard OA. TET2, a tumor suppressor in hematological disorders. Biochim Biophys Acta 2012; 1825: 173-177.
Jones PA, Laird PW. Cancer-epigenetics comes of age. Nat Genet 1999; 21: 163-167.
Huang Y, Rao A. Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet 2014; 30: 464-474.
García MG, Carella A, Urdinguio RG, et al. Epigenetic dysregulation of TET2 in human glioblastoma. Oncotarget 2018; 9: 25922-25934.
Kohanbash G, Carrera DA, Shrivastav S, et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest 2017; 127: 1425-1437.
Lucca LE, Hafler DA. Resisting fatal attraction: A glioma oncometabolite prevents CD8+T cell recruitment. J Clin Invest 2017; 127: 1218-1220.
Yang W, Wang H, Ju H, Dou C. A study on the correlation between STAT‑1 and mutant p53 expression in glioma. Mol Med Rep 2018; 17: 7807-7812.
Berghoff AS, Kiesel B, Widhalm G, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol 2017; 19: 1460-1468.
Amankulor NM, Kim Y, Arora S, et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev 2017; 31: 774-786.
Mu L, Long Y, Yang C, et al. The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas. Front Mol Neurosci 2018; 11: 82.
Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423-1437.
Rahman M, Kresak J, Yang C, et al. Analysis of immunobiologic markers in primary and recurrent glioblastoma. J Neurooncol 2018; 137: 249-257.
Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216: 15-24.
Ma C, Horlad H, Ohnishi K, et al. CD163-positive cancer cells are potentially associated with high malignant potential in clear cell renal cell carcinoma. Med Mol Morphol 2018; 51: 13-20.
Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M. RNA Interference Targeting Transforming Growth Factor- Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In vivo. Cancer Res 2004; 64: 7596-7603.
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. J Exp Med 2000; 192: 1027-1034.
Goodman AM, Piccioni D, Kato S, et al. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol 2018; 4: 1237-1244.
Gerlinger M, McGranahan N, Dewhurst SM, Burrell RA, Tomlinson I, Swanton C. Cancer: Evolution Within a Lifetime. Annu Rev Genet 2014; 48: 215-236.
Falnes PØ, Johansen RF, Seeberg E. AlkB-mediated oxidative demethylation reverses DNA damage in Escherichia coli. Nature 2002; 419: 178-182.
Wang P, Wu J, Ma S, et al. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Rep 2015; 13: 2353-2361.
Cairncross JG, Wang M, Jenkins RB, et al. Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH. J Clin Oncol 2014; 32: 783-790.
Johannessen T-CA, Prestegarden L, Grudic A, Hegi ME, Tysnes BB, Bjerkvig R. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells. Neuro Oncol 2013; 15: 269-278.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe